Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Tolerance to self-antigens prevents the elimination of cancer by the immune system(1,2). We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL). Remission was induced in a subset of subje...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Med
Autors principals: Fraietta, Joseph A., Lacey, Simon F., Orlando, Elena J., Pruteanu-Malinici, Iulian, Gohil, Mercy, Lundh, Stefan, Boesteanu, Alina C., Wang, Yan, O’Connor, Roddy S., Hwang, Wei-Ting, Pequignot, Edward, Ambrose, David E., Zhang, Changfeng, Wilcox, Nicholas, Bedoya, Felipe, Dorfmeier, Corin, Chen, Fang, Tian, Lifeng, Parakandi, Harit, Gupta, Minnal, Young, Regina M., Johnson, F. Brad, Kulikovskaya, Irina, Liu, Li, Xu, Jun, Kassim, Sadik H., Davis, Megan M., Levine, Bruce L., Frey, Noelle V., Siegel, Donald L., Huang, Alexander C., Wherry, E. John, Bitter, Hans, Brogdon, Jennifer L., Porter, David L., June, Carl H., Melenhorst, J. Joseph
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6117613/
https://ncbi.nlm.nih.gov/pubmed/29713085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-018-0010-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars